ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

ClinicalTrials.gov ID: NCT01811732

Public ClinicalTrials.gov record NCT01811732. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 7:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections

Study identification

NCT ID
NCT01811732
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Enrollment
660 participants

Conditions and interventions

Interventions

  • Aztreonam Drug
  • Delafloxacin Drug
  • Placebo Drug
  • Vancomycin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2013
Primary completion
Jun 30, 2014
Completion
Jun 30, 2014
Last update posted
Sep 26, 2017

2013 – 2014

United States locations

U.S. sites
17
U.S. states
9
U.S. cities
17
Facility City State ZIP Site status
Melinta Investigational Site Montgomery Alabama 36106
Melinta Investigational Site Anaheim California 92804
Melinta Investigational Site Chula Vista California 91911
Melinta Investigational Site La Mesa California 91942
Melinta Investigational Site Long Beach California 90813
Melinta Investigational Site Los Angeles California 90015
Melinta Investigational Site Modesto California 95350
Melinta Investigational Site Oceanside California 92056
Melinta Investigational Site Pasadena California 91105
Melinta Investigational Site Stockton California 95204
Melinta Investigational Site Miramar Florida 33027
Melinta Investigational Site Minneapolis Minnesota 55422
Melinta Investigational Site Butte Montana 59701
Melinta Investigational Site Las Vegas Nevada 89109
Melinta Investigational Site Somers Point New Jersey 08244
Melinta Investigational Site Smyrna Tennessee 37167
Melinta Investigational Site Richmond Texas 77469

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01811732, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 26, 2017 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01811732 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →